Fri Jun 22, 2012 10:02am EDT (Reuters) – Repligen Corp said U.S. health regulators denied approval for its imaging agent to detect structural abnormalities in the pancreas, sending its shares down 10 percent. The U.S
SP Clinic 1519/69-70 Ladproud 41/1 Samsennog Huaykuang Bangkok 10310, Thailand
Mobile Phone For English please call + 6681 9011 030
Tel. +662 9304450-5 Fax. +662 9399061
email: email@example.com firstname.lastname@example.org
Website Designed, and Developed by RedOnion Co.,Ltd.